Yes, CBD is extensively metabolized by the liver. In fact, the liver is so central to CBD processing that roughly 70 to 75% of an oral dose is broken down during its very first pass through the organ before reaching the bloodstream. This has real implications for how much CBD your body actually absorbs, how it interacts with other medications, and whether it poses any risk to liver health.
How the Liver Breaks Down CBD
When you swallow CBD, it travels from your gut to the liver through the portal vein. There, a family of enzymes begins breaking it apart. Two enzymes, CYP2C19 and CYP2C9, handle the first major step: converting CBD into an active metabolite called 7-OH-CBD. CYP2C19 does about 69% of this work, with CYP2C9 contributing the remaining 31%. A third enzyme, CYP3A4, breaks CBD down through separate pathways, producing different byproducts.
That active metabolite, 7-OH-CBD, appears to have similar pharmacological effects to CBD itself. It then gets processed further by CYP3A4 into an inactive compound, 7-COOH-CBD, which actually builds up to higher concentrations in the blood than CBD itself. Because this inactive metabolite is less fat-soluble and likely doesn’t cross into the brain as easily, it’s considered pharmacologically inert.
This heavy first-pass metabolism explains why oral CBD has relatively low bioavailability. With three-quarters of the dose cleared before it even circulates, the amount of CBD that reaches your tissues is a fraction of what you swallowed.
How Long CBD Stays in Your System
CBD has a surprisingly long terminal half-life, exceeding 134 hours in humans. That’s more than five and a half days. The reason isn’t that the liver works slowly, but that CBD distributes extensively into fat and other tissues, then slowly trickles back into the bloodstream for processing. If you take CBD daily, your plasma levels won’t reach a true steady state for over 70 days. This is worth knowing if you’re evaluating whether CBD is “working” after just a week or two of use.
CBD’s Effect on Liver Health
Because the liver does so much of the metabolic heavy lifting, high doses of CBD can stress the organ. In an FDA-conducted randomized trial, healthy participants took CBD at doses of roughly 250 to 550 mg per day for 28 days. About 5.6% of those receiving CBD developed liver enzyme elevations (ALT levels exceeding three times the upper limit of normal), and 4.9% met criteria for potential drug-induced liver injury. These elevations typically appeared after about two weeks of dosing and were dose-dependent.
The good news: none of the participants in that study developed clinical symptoms of liver problems, and their enzyme levels returned to normal within one to two weeks after stopping CBD. Still, this is why the FDA requires liver function testing for patients prescribed pharmaceutical-grade CBD. The recommended monitoring schedule includes bloodwork before starting treatment, then at one month, three months, and six months, with additional testing after any dose change.
For the lower doses found in consumer CBD products (often under 200 mg per day), the safety data is more limited and inconsistent. The FDA has noted that additional research at these dose ranges is still needed.
Drug Interactions From Shared Liver Enzymes
CBD doesn’t just get processed by liver enzymes. It also blocks several of them from doing their normal jobs. CBD competitively inhibits CYP3A4, CYP2C9, CYP2D6, CYP2B6, and CYP2E1. When these enzymes are occupied by CBD, other medications that rely on them can build up to higher (and potentially dangerous) levels in the blood.
The list of affected drug classes is broad:
- Blood thinners: Warfarin relies on CYP2C9 and CYP3A4 for clearance. CBD can increase warfarin levels, raising bleeding risk.
- Immunosuppressants: Drugs like tacrolimus, cyclosporine, and everolimus are processed by CYP3A4. One study found everolimus exposure increased by 180% when combined with cannabis-derived products.
- Anti-seizure medications: Brivaracetam levels can rise 107 to 280% due to CYP2C19 inhibition. Clobazam, commonly co-prescribed with pharmaceutical CBD for epilepsy, also sees significant increases.
- Opioids: Methadone exposure increased by about 117% through CYP3A4 and CYP2C19 inhibition.
- SSRIs: Citalopram, processed by both CYP3A4 and CYP2C19, has a possible interaction with CBD.
- Caffeine: Even caffeine clearance slows modestly, as CBD inhibits CYP1A2.
The interaction works in the other direction too. Drugs that strongly activate or block CYP3A4 can change how much CBD your body absorbs. Ketoconazole (an antifungal) increased CBD exposure by up to 204%, while rifampicin (an antibiotic) reduced it by as much as 87%.
Liver Disease Changes the Equation
If your liver is already compromised, it clears CBD much more slowly. A clinical trial measured this directly across different levels of liver impairment. People with mild liver disease saw a modest 48% increase in CBD exposure, which wasn’t considered clinically significant. But moderate impairment led to a 2.5-fold increase, and severe impairment caused a fivefold increase in CBD blood levels compared to people with healthy livers.
The liver’s clearance rate tells the same story in reverse. Healthy livers cleared CBD at about 422 liters per hour. With moderate impairment, that dropped to 172 liters per hour. With severe impairment, just 82 liters per hour. Based on these findings, dose reductions are recommended: roughly half the normal dose for moderate liver disease and one-fifth for severe liver disease. No adjustment is needed for mild impairment.
Genetics Affect How Fast You Process CBD
Not everyone’s liver enzymes work at the same speed. Genetic variations in CYP2C19, CYP2C9, and CYP3A5 create natural differences in how quickly people metabolize CBD. A study in healthy volunteers found that CYP2C19 intermediate metabolizers (people with a genetically slower version of the enzyme) had lower CBD exposure after a single dose, likely because the enzyme converts CBD into its active metabolite at a different rate, shifting the balance between parent drug and metabolites.
At steady state, the picture shifted slightly. CYP2C9 intermediate and poor metabolizers showed CBD peak levels about 73% higher than normal metabolizers. These are modest differences for most people, but they help explain why two individuals taking the same CBD dose can have noticeably different responses. If you’ve tried CBD and found it either surprisingly strong or surprisingly weak compared to what others report, your genetics may be part of the reason.